
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is attractive because it continues to deliver strong volume growth, with 3Q26 US procedures up 20% and revenue of $55.7 million rising 14.5% year over year despite a softer orthopedic backdrop. Reaffirmed FY2026 guidance of $231-233 million implies roughly 15-16% growth and about 20% fourth-quarter growth at the midpoint, while gross margin remained high at 79.3% and adjusted EBITDA beat expectations at $3.0 million. The outlook is supported by an expanding surgeon base, improving reimbursement, and the early launch of Onyx and Granite, which together broaden the addressable market and create a path to faster growth and profitability.
Bears say
SI-BONE is facing a bearish setup because the bear case assumes only single-digit revenue growth in the U.S. with margin improvement stalling, suggesting the company may struggle to scale profitably even as it continues commercializing its implant franchise. Competitive launches, iFuse patent expirations, poor sales force execution, unfavorable market dynamics, and slower progress toward profitability all point to erosion in pricing power, growth durability, and operating leverage. The valuation framework also implies limited confidence in the outlook, as the bear case is tied to a 1.5x EV/sales multiple on the 2027E estimate, reinforcing the view that fundamentals remain challenged.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About SI-BONE Inc (SIBN) Forecast
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares